Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naldebain + SafeTynadol
- Development stage
- Unknown
- Lead developer
- Sinew Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Naldebain + SafeTynadol is a combination analgesic therapy being developed by Sinew Pharma Inc. for the management of moderate to severe postoperative pain, specifically following knee replacement surgery. The combination consists of Naldebain (sebacoyl dinalbuphine ester), a long-acting prodrug of the opioid analgesic nalbuphine, and SafeTynadol (SNP-810), a liver-safe formulation of acetaminophen. Nalbuphine acts as a kappa-opioid receptor agonist and a mu-opioid receptor antagonist, providing potent analgesia with a lower risk of respiratory depression and addiction compared to traditional mu-agonists. SafeTynadol is designed to provide the analgesic and antipyretic benefits of acetaminophen while utilizing specific additives (mannitol and sucralose) to inhibit the metabolic pathways that lead to hepatotoxic metabolites like NAPQI. This combination aims to provide synergistic pain relief with an improved safety profile.
- Brand names
- SafeTynadol
- Other names
- sebacoyl dinalbuphine ester + acetaminophen
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Naldebain + SafeTynadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naldebain + SafeTynadol.